Post-marketing safety concerns with montelukast: A pharmacovigilance study based on the FDA adverse event reporting system
Int. Journal of Clinical Pharmacology and Therapeutics · 2024
DOI: 10.5414/cp204560 ↗Kurz gefasst
Fachartikel in der Zeitschrift Int. Journal of Clinical Pharmacology and Therapeutics, 2024. Verfasst von Zhimin Ou und 5 weiteren Autor:innen. Hauptthemen laut MEDLINE: Acetates, Cyclopropanes, Quinolines, Pharmacovigilance. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Ou, Z., Han, Y., Zhuang, W., Xiao, Y., Cai, S., & Zhang, X. (2024). Post-marketing safety concerns with montelukast: A pharmacovigilance study based on the FDA adverse event reporting system. Int. Journal of Clinical Pharmacology and Therapeutics. https://doi.org/10.5414/cp204560
Vancouver
Ou Z, Han Y, Zhuang W, Xiao Y, Cai S, Zhang X. Post-marketing safety concerns with montelukast: A pharmacovigilance study based on the FDA adverse event reporting system. Int. Journal of Clinical Pharmacology and Therapeutics. 2024. doi:10.5414/cp204560
BibTeX
@article{Ou2024,
author = {Ou, Zhimin and Han, Ying and Zhuang, Wei and Xiao, Yunshan and Cai, Shuying and Zhang, Xueqin},
title = {Post-marketing safety concerns with montelukast: A pharmacovigilance study based on the FDA adverse event reporting system},
journal = {Int. Journal of Clinical Pharmacology and Therapeutics},
year = {2024},
doi = {10.5414/cp204560}
}
EUVIMED